[Evaluation of the expression of p22 phox subunit of NADPH oxidase (NOX) in prostate cancer and benign prostatic hyperplasia: a comparative study]

INTRODUCTION AND OBJECTIVE

Recent reports found that prostate cancer is the second most common cancer and second leading cause of cancer death in men.

METHODS AND RESULTS

62 samples were obtained (30 of patients with cancer and 32 of patients with hyperplasia) collected from January 2004 to december 2007. Was conducted a clinical, experimental, transversal, comparative and descriptive trial. Were followed the inclusion (cancer or hyperplasia diagnosis), exclusion (patients not authorized to participate in the study or not candidates for resection of prostate) and elimination (damage tissue) criteria. Was detected by immunohistochemistry the presence of p22 phox NADPH oxidase subunit in patients with prostate cancer and prostatic hyperplasia from the formation of avidin-biotin complex using diaminobenzidine as a dye contrast. The statistical analysis was determined with t test (Graph Prism 3.0 software) considering p<0.05 for statistical differences. The results of the immunoreactivity of p22 phox in the stroma and gland of the prostate showed an increase in prostate cancer (8.45+/-3.6 and 25.08+/-7.5% p<0.0001, respectively) in comparison with the results for prostatic hyperplasia (4.8+/-2.8 and 6.7+/-3.1% p<0.0001, respectively).

CONCLUSIONS

The over-expression of the NADPH oxidase is involved in the prostate cancer. Moreover, we suggested that the NADPH oxidase, in combination with other classical markers, could be an indicator for the post-treatment monitoring of the patients diagnosed with hyperplasia and others minors pathologies of the prostate.

DD3PCA3 gene expression in cancer and prostatic hyperplasia

Purpose: DD3PCA3 is a novel gene with characteristics that indicate its potentially valuable role in early identification and diagnosis of malignancy and highly upregulated in transformed cells in PCa. The aim of this work was to validate and analyze, by real-time Reverse Transcription-Polymerase Chain Reaction (RT-PCR), the expression of the DD3PCA3 gene in a mexican population, both in intratumoral tissue with PCa and benign prostatic hyperplasia (BPH). Methods: Human samples from patients with PCa (40 cases) and benign prostatic hyperplasia (40 cases) were analyzed for the mRNA expression of DD3PCA3 by RT-PCR Results: The GAPDH gene showed better stability with a Pearson correlation of 0.953 (P < 0.007) for the determination of housekeeping gene. DD3PCA gene expression was 29.74 times higher in PCa tissue (P < 0.0001) than in BPH. The gene expression for the PCa and BPH was 1731±280 and 58.23±9.9 fold, respectively. Conclusions: Determination of DD3PCA3 gene expression by RT-PCR could be a potentially tool for the early detection of PCa in clinical specimens.

DD3(PCA3) gene expression in cancer and prostatic hyperplasia

PURPOSE

DD3(PCA3) is a novel gene with characteristics that indicate its potentially valuable role in early identification and diagnosis of malignancy and highly upregulated in transformed cells in PCa. The aim of this work was to validate and analyze, by real-time Reverse Transcription-Polymerase Chain Reaction (RT-PCR), the expression of the DD3(PCA3)gene in a Mexican population, both in intratumoral tissue with PCa and benign prostatic hyperplasia (BPH).

METHODS

Human samples from patients with PCa (40 cases) and benign prostatic hyperplasia (40 cases) were analyzed for the mRNA expression of DD3(PCA3)by RT-PCR RESULTS: The GAPDH gene showed better stability with a Pearson correlation of 0.953 (P < 0.007) for the determination of housekeeping gene. DD3(PCA3)gene expression was 29.74 times higher in PCa tissue (P < 0.0001) than in BPH. The gene expression for the PCa and BPH was 1731+/-280 and 58.23+/-9.9 fold, respectively.

CONCLUSIONS

Determination of DD3(PCA3)gene expression by RT-PCR could be a potentially tool for the early detection of PCa in clinical specimens.